

Efecto de los bloqueantes del sistema renina-angiotensina, solos o combinados

Referencias

1. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. *J Am Soc Nephrol.* 2003;14: 3217-32.
2. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *J Clin Invest.* 2006;116: 288-96.
3. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int.* 2004;65:2309-20.
4. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. *J Am Soc Nephrol.* 2002;13:1100-8.
5. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med.* 2004;351:1952-61
6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med.* 2001;345:870-8
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001;345:851-60.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001;345:861-9.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* 2002;39:S1-266.
10. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. *Ann Intern Med.* 2005;142:510-24.
11. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol.* 2005;5: 13.
12. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. *Stat Med.* 2002;21:2161-73.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21:1539-58.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557-60.
15. Cochran W. The combination of estimates from different experiments. *Biometrics.* 1954;10:101-9.
16. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. *Systematic reviews in health care: metaanalysis in context.* 2nd ed. London: BMJ Publishing; 2001: 285-312.
17. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. *BMJ.* 2006;333:597-600.
18. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. *Quality of Reporting of Meta-analyses.* *Lancet.* 1999;354:1896-900.
19. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting- enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. *Lancet.* 2003;361:117-24.
20. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. *Nephrol Dial Transplant.* 2002;17:597-601.
21. Kim MJ, Song JH, Suh JH, Lee SW, Kim GA. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. *Yonsei Med J.* 2003;44:463-72.
22. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ando N, Ohta S, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. *Hypertens Res.* 2005;28:865-70.
23. Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. *Kidney Int.* 2003;64:1450-4.

24. Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. *Nephrol Dial Transplant.* 1998;13:3096-102.
25. Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. *Nephrol Dial Transplant.* 2003;18:1115-21.
26. Praga M, Andrade CF, Lun˜o J, Arias M, Poveda R, Mora J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. *Nephrol Dial Transplant.* 2003;18:1806-13.
27. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation.* 2002;106:672-8.
28. Yasuda G, Ando D, Hirawa N, Umemura S, Tochikubo O. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. *Diabetes Care.* 2005;28:1862-8.
29. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. *Am J Kidney Dis.* 2005;45:281-7.
30. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. *JAMA.* 2001;285:437-43.
31. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med.* 1999;341:709-17.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med.* 2004;351:543-51.
33. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. *Kidney Int.* 2002;62:1020-5.
34. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. *J Am Soc Nephrol.* 2005;16:3038-45.
35. Bucher HC, Kunz R, Cook D, Holbrook A, Guyatt G. Surrogate Outcomes. In: Guyatt G, Rennie D, eds. *User's Guides to the Medical Literature.* 2nd ed. 2007.
36. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? *Kidney Int.* 1994;45:861-7.
37. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. *Int J Epidemiol.* 2002;31:140-9.
38. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med.* 2001;135:73-87.
39. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. *Kidney Int.* 2000;57:601-6.
40. Haneda M, Kikkawa R, Sakai H, Kawamori R; Candesartan in Diabetic Nephropathy Study Group. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. *Diabetes Res Clin Pract.* 2004;66:87-95.
41. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. *J Am Soc Nephrol.* 2003;14:992-9.
42. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al.; HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. *Am J Kidney Dis.* 2006;47:751-60.
43. Muirhead F, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Bottori F, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo controlled trial. *Curr Ther Res Clin Exp.* 1999;60:650-60.
44. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. *Diabetes Care.* 2003;26:150-5.
45. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. *Diabetes Care.* 2002;25:1909-13.
46. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. *Ann Intern Med.* 2003; 139:90-6.

47. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, et al.; Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. *Hypertens Res.* 2004;27:21-30.
48. Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. *Nephron Clin Pract.* 2005;99:c18-23.
49. Campbell R, Sangalli F, Peticucci E, Aros C, Viscarra C, Perna A, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. *Kidney Int.* 2003;63:1094-103. 50.
50. Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. *Int J Clin Pract.* 2004;58:432-5
51. Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. *J Am Soc Nephrol.* 2005;16:474-81.
52. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. *J Hypertens.* 2002;20:125-30.
53. Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. *Hypertens Res.* 2004;27:963-70. 54
54. Lacourcière Y, Be' langer A, Godin C, Halle' JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. *Kidney Int.* 2000;58:762-9.
55. Lunö J, Barrio V, Goicoechea MA, Gonzá'lez C, De Vinuesa SG, Go'mez F, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. *Kidney Int.* 2002;62 Suppl 82:47-52.
56. Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. *Clin Nephrol.* 2005;64:180-9.
57. Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. *Hypertens Res.* 2003;26:875-80.
58. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ.* 2000; 321:1440-4.
59. Renke M, Tylicki L, Rutkowski P, Rutkowski B. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. *Scand J Urol Nephrol.* 2004;38:427-33. 60.
60. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. *Am J Kidney Dis.* 2001;38:18-25.
61. Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. *Am J Kidney Dis.* 2004;43:260-8.
62. Schulz E, Bech J, Pedersen EB, Zavala R, Ruiz M, Muller GA. Tolerability and antihypertensive efficacy of losartan vs captopril in patients with mild to moderate hypertension and impaired renal function. A randomised, doubleblind, parallel study. *Clin Drug Invest.* 2000;19:183-94.
63. Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. *J Renin Angiotensin Aldosterone Syst.* 2003;4:43-7.
64. Sengul AM, Altuntas Y, Ku'rklu' A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. *Diabetes Res Clin Pract.* 2006;71:210-9.
65. Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. *Nephrol Dial Transplant.* 2006; 21:683-9.
66. Tütücü NB, Gürlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. *Acta Diabetol.* 2001;38:157-61.]
67. Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydłowska W. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. *Med Sci Monit.* 2005;11:PI31-7. 68.

68. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. *J Hypertens*. 2000;18:89-95.
69. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. *Kidney Int*. 2001;59:2282-9.
70. Berger ED, Bader BD, Ebert C, Risler T, Erley CM. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. *J Hypertens*. 2002;20:739-43.
71. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. *Nephrol Dial Transplant*. 2002;17:1019-24.
72. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. *Kidney Int*. 2003;63:1874-80.
73. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. *Diabetes Care*. 2002;25:95-100.
74. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. *Diabetes Care*. 2003;26:2268-74.